Todd Michael Cooper, DO

Cancer and Blood Disorders Center, Leukemia and Lymphoma Program, High-Risk Leukemia Program

On staff since February 2015

Children's Title: Co-Interim Division Chief, Hematology-Oncology; Evans Family Endowed Chair in Pediatric Cancer

Research Center: Center for Clinical and Translational Research

  • Todd M. Cooper, DO, is an attending physician at Seattle Children's Hospital, Professor of Pediatrics at the University of Washington School of Medicine, and Evan's Family Endowed Chair in Pediatric Cancer. Dr. Cooper is the Director of the Pediatric Leukemia/Lymphoma Program and Co-Director of the High-Risk Leukemia Program.

    Dr. Todd Cooper's interests and expertise focus on the development of new therapeutic strategies for the treatment of acute leukemia in children. Prior to coming to Seattle, Dr. Cooper developed and provided leadership for Phase I/Developmental Therapeutics programs at the University of Alabama at Birmingham and Children’s Healthcare of Atlanta/Emory University.  Dr. Cooper has led Phase I studies of new agents for relapsed acute leukemia in a variety of national consortia including the Therapeutic Advances for Childhood Leukemia (TACL) Consortium, Pediatric Oncology Experimental Therapeutics Investigator Consortium (POETIC), and the Children’s Oncology Group (COG) Consortium. Dr. Cooper serves as the chair of the COG Acute Myeloid Leukemia (AML) New Agents Committee and actively collaborates internationally to help maintain a cohesive strategy for the treatment of children with acute leukemia.  Dr. Cooper leads  COG AAML1831, a COG Phase III study for newly diagnosed children with AML. Dr. Cooper is als the clinical trial lead for a Leukemia/Lymphoma Society-funded master trial for relapsed pediatric acute leukemia (PedAL). This international trial will match children with novel targeted therapies based on centralized next generation genomic sequencing. These opportunities have allowed me to engage with the FDA and EMA in discussing individual new drugs and general clinical trial designs for children with relapsed acute leukemia. I am intimately involved in the selection of new agents, designing and leading clinical trials, all with the goal of bringing positive change to the therapy of children diagnosed with AML both nationally and internationally.     

     

    • Related Resources

    • Hilda Atlanta, GA 01.14.20

      Doctor Cooper is the best !! I’m thankful to God for this wonderful doctor in my journey’s son. I always praying for him. God bless.

    • Kadee San Diego, CA 10.29.17

      While living in Bothell, WA we had the privilege of having Dr Cooper as our son’s doctor. He provided a sense of calm and peace during a very trying time. His bedside manner and knowledge was unsurpassed. We have since left the area and miss Dr Cooper very much. No one will ever measure up.

  • Other Publications

    • Karol SE, Cooper TM, Mead PE, Crews KR, Panetta JC, Alexander TB, Taub JW, Lacayo NJ, Heym KM, Kuo DJ, Schiff DE, Bhojwani D, Ge Y, Klco JM, Ribeiro RC, Inaba H, Pui CH, Rubnitz JE
      Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia.
      32809242 Cancer, 2020 Nov. 1 : 126(21)4800-4805 PMCID:PMC7722063
    • Karol SE, Cooper TM, Mead PE, Crews KR, Panetta JC, Alexander TB, Taub JW, Lacayo NJ, Heym KM, Kuo DJ, Schiff DE, Bhojwani D, Ge Y, Klco JM, Ribeiro RC, Inaba H, Pui CH, Rubnitz JE
      Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia.
      32809242 Cancer, 2020 Nov. 1 : 126(21)4800-4805 PMCID:PMC7722063
    • Pearson ADJ, Zwaan CM, Kolb EA, Karres D, Guillot J, Kim SY, Marshall L, Tasian SK, Smith M, Cooper T, Adamson PC, Barry E, Benettaib B, Binlich F, Borgman A, Brivio E, Capdeville R, Delgado D, Faller D, Fogelstrand L, Fraenkel PG, Hasle H, Heenen D, Kaspers G, Kieran M, Klusmann JH, Lesa G, Ligas F, Mappa S, Mohamed H, Moore A, Morris J, Nottage K, Reinhardt D, Scobie N, Simko S, Winkler T, Norga K, Reaman G, Vassal G
      Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
      32688206 European journal of cancer (Oxford, England : 1990), 2020 Sept. : 136116-129
    • Pearson ADJ, Zwaan CM, Kolb EA, Karres D, Guillot J, Kim SY, Marshall L, Tasian SK, Smith M, Cooper T, Adamson PC, Barry E, Benettaib B, Binlich F, Borgman A, Brivio E, Capdeville R, Delgado D, Faller D, Fogelstrand L, Fraenkel PG, Hasle H, Heenen D, Kaspers G, Kieran M, Klusmann JH, Lesa G, Ligas F, Mappa S, Mohamed H, Moore A, Morris J, Nottage K, Reinhardt D, Scobie N, Simko S, Winkler T, Norga K, Reaman G, Vassal G
      Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
      32688206 European journal of cancer (Oxford, England : 1990), 2020 Sept. : 136116-129
    • Getz KD, Sung L, Alonzo TA, Leger KJ, Gerbing RB, Pollard JA, Cooper T, Kolb EA, Gamis AS, Ky B, Aplenc R
      Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
      32343641 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 July 20 : 38(21)2398-2406 PMCID:PMC7367546
    • Getz KD, Sung L, Alonzo TA, Leger KJ, Gerbing RB, Pollard JA, Cooper T, Kolb EA, Gamis AS, Ky B, Aplenc R
      Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
      32343641 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 July 20 : 38(21)2398-2406 PMCID:PMC7367546
    • Cooper TM, Absalon MJ, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA, Pollard J, Razzouk BI, Aplenc R, Kolb EA
      Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
      32401633 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 July 1 : 38(19)2170-2177 PMCID:PMC7325367
    • Cooper TM, Absalon MJ, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA, Pollard J, Razzouk BI, Aplenc R, Kolb EA
      Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
      32401633 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 July 1 : 38(19)2170-2177 PMCID:PMC7325367
    • Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA
      Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
      31969338 Clinical cancer research : an official journal of the American Association for Cancer Research, 2020 May 15 : 26(10)2297-2307 PMCID:PMC7477726
    • Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA
      Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
      31969338 Clinical cancer research : an official journal of the American Association for Cancer Research, 2020 May 15 : 26(10)2297-2307 PMCID:PMC7477726
    • Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, Gust J, Leger KJ, Tarlock K, Cooper TM, Finney OC, Brakke H, Li DH, Park JR, Jensen MC
      Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
      31697826 Blood, 2019 Dec. 12 : 134(24)2149-2158 PMCID:PMC6908832
    • Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, Gust J, Leger KJ, Tarlock K, Cooper TM, Finney OC, Brakke H, Li DH, Park JR, Jensen MC
      Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
      31697826 Blood, 2019 Dec. 12 : 134(24)2149-2158 PMCID:PMC6908832
    • McNeil MJ, Parisi MT, Hijiya N, Meshinchi S, Cooper T, Tarlock K
      Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin.
      29734213 Journal of pediatric hematology/oncology, 2019 April : 41(3)e174-e176
    • McNeil MJ, Parisi MT, Hijiya N, Meshinchi S, Cooper T, Tarlock K
      Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin.
      29734213 Journal of pediatric hematology/oncology, 2019 April : 41(3)e174-e176
    • Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA
      Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
      29728694 Leukemia, 2018 Nov. : 32(11)2316-2325 PMCID:PMC6224404
    • Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA
      Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
      29728694 Leukemia, 2018 Nov. : 32(11)2316-2325 PMCID:PMC6224404
    • Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, Hijiya N, Gore L, Cooper TM, Loh ML, Roti G, Neuberg DS, Hunt SK, Orloff-Parry S, Stegmaier K, Sallan SE, Silverman LB
      Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
      29603593 Pediatric blood & cancer, 2018 July : 65(7)e27062
    • Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, Gao Y, Wall D, Mazor T, Olshen AB, Parker JS, Kahwash S, Hirsch B, Raimondi S, Patel N, Skeens M, Cooper T, Mehta PA, Grupp SA, Loh ML
      Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
      29528181 Pediatric blood & cancer, 2018 July : 65(7)e27034 PMCID:PMC5980696
    • Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, Gao Y, Wall D, Mazor T, Olshen AB, Parker JS, Kahwash S, Hirsch B, Raimondi S, Patel N, Skeens M, Cooper T, Mehta PA, Grupp SA, Loh ML
      Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
      29528181 Pediatric blood & cancer, 2018 July : 65(7)e27034 PMCID:PMC5980696
    • Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, Hijiya N, Gore L, Cooper TM, Loh ML, Roti G, Neuberg DS, Hunt SK, Orloff-Parry S, Stegmaier K, Sallan SE, Silverman LB
      Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
      29603593 Pediatric blood & cancer, 2018 July : 65(7)e27062
    • Sun W, Triche T Jr, Malvar J, Gaynon P, Sposto R, Yang X, Bittencourt H, Place AE, Messinger Y, Fraser C, Dalla-Pozza L, Salhia B, Jones P, Wayne AS, Gore L, Cooper TM, Liang G
      A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.
      29339403 Blood, 2018 March 8 : 131(10)1145-1148 PMCID:PMC5863703
    • Sun W, Triche T Jr, Malvar J, Gaynon P, Sposto R, Yang X, Bittencourt H, Place AE, Messinger Y, Fraser C, Dalla-Pozza L, Salhia B, Jones P, Wayne AS, Gore L, Cooper TM, Liang G
      A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.
      29339403 Blood, 2018 March 8 : 131(10)1145-1148 PMCID:PMC5863703
    • Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA
      A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
      28409853 Pediatric blood & cancer, 2017 Aug. : 64(8) PMCID:PMC5675008
    • Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA
      A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
      28409853 Pediatric blood & cancer, 2017 Aug. : 64(8) PMCID:PMC5675008
    • Gore L, Triche TJ Jr, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B
      A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
      29034009 Clinical epigenetics, 2017 : 9108 PMCID:PMC5629751
    • Gore L, Triche TJ Jr, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B
      A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
      29034009 Clinical epigenetics, 2017 : 9108 PMCID:PMC5629751
    • von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L
      Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
      27998223 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016 Dec. 20 : 34(36)4381-4389
    • von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L
      Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
      27998223 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016 Dec. 20 : 34(36)4381-4389
    • Raikar SS, Scarborough JD, Sabnis H, Bergsagel J, Wu D, Cooper TM, Keller FG, Wood BL, Bunting ST
      Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia.
      27145535 Pediatric blood & cancer, 2016 Sept. : 63(9)1667-70
    • Raikar SS, Scarborough JD, Sabnis H, Bergsagel J, Wu D, Cooper TM, Keller FG, Wood BL, Bunting ST
      Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia.
      27145535 Pediatric blood & cancer, 2016 Sept. : 63(9)1667-70
    • Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA
      A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
      26920889 Clinical cancer research : an official journal of the American Association for Cancer Research, 2016 Aug. 15 : 22(16)4014-22
    • Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA
      A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
      26920889 Clinical cancer research : an official journal of the American Association for Cancer Research, 2016 Aug. 15 : 22(16)4014-22
    • Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, Loh ML
      Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia.
      26711114 Nature genetics, 2016 Jan. : 48(1)101
    • Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, Loh ML
      Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia.
      26711114 Nature genetics, 2016 Jan. : 48(1)101
    • Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen S, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber T, Golub T, Stegmaier K, Loh ML
      The genomic landscape of juvenile myelomonocytic leukemia.
      26457647 Nature genetics, 2015 Nov. : 47(11)1326-1333 PMCID:PMC4626387
    • Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen S, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber T, Golub T, Stegmaier K, Loh ML
      The genomic landscape of juvenile myelomonocytic leukemia.
      26457647 Nature genetics, 2015 Nov. : 47(11)1326-1333 PMCID:PMC4626387
    • Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, Meshinchi S, Pollard JA
      Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
      25662999 Pediatric blood & cancer, 2015 June : 62(6)1048-54
    • Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, Meshinchi S, Pollard JA
      Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
      25662999 Pediatric blood & cancer, 2015 June : 62(6)1048-54
    • Stieglitz E, Ward AF, Gerbing RB, Alonzo TA, Arceci RJ, Liu YL, Emanuel PD, Widemann BC, Cheng JW, Jayaprakash N, Balis FM, Castleberry RP, Bunin NJ, Loh ML, Cooper TM
      Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
      25704135 Pediatric blood & cancer, 2015 April : 62(4)629-36 PMCID:PMC4339233
    • Stieglitz E, Ward AF, Gerbing RB, Alonzo TA, Arceci RJ, Liu YL, Emanuel PD, Widemann BC, Cheng JW, Jayaprakash N, Balis FM, Castleberry RP, Bunin NJ, Loh ML, Cooper TM
      Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
      25704135 Pediatric blood & cancer, 2015 April : 62(4)629-36 PMCID:PMC4339233
    • Liu X, Zheng H, Yu WM, Cooper TM, Bunting KD, Qu CK
      Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming cellular metabolism.
      25593337 Blood, 2015 March 5 : 125(10)1562-5 PMCID:PMC4351504
    • Liu X, Zheng H, Yu WM, Cooper TM, Bunting KD, Qu CK
      Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming cellular metabolism.
      25593337 Blood, 2015 March 5 : 125(10)1562-5 PMCID:PMC4351504
    • Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, Meshinchi S, Pollard JA
      Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
      25662999 Pediatric blood & cancer, 2015 Feb. 8
    • Niemeyer CM, Loh ML, Cseh A, Cooper T, Dvorak CC, Chan R, Xicoy B, Germing U, Kojima S, Manabe A, Dworzak M, De Moerloose B, Starý J, Smith OP, Masetti R, Catala A, Bergstraesser E, Ussowicz M, Fabri O, Baruchel A, Cavé H, Zwaan M, Locatelli F, Hasle H, van den Heuvel-Eibrink MM, Flotho C, Yoshimi A
      Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.
      25552679 Haematologica, 2015 Jan. : 100(1)17-22 PMCID:PMC4281308
    • Niemeyer CM, Loh ML, Cseh A, Cooper T, Dvorak CC, Chan R, Xicoy B, Germing U, Kojima S, Manabe A, Dworzak M, De Moerloose B, Starý J, Smith OP, Masetti R, Catala A, Bergstraesser E, Ussowicz M, Fabri O, Baruchel A, Cavé H, Zwaan M, Locatelli F, Hasle H, van den Heuvel-Eibrink MM, Flotho C, Yoshimi A
      Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.
      25552679 Haematologica, 2015 Jan. : 100(1)17-22 PMCID:PMC4281308
    • Niemeyer CM, Loh ML, Cseh A, Cooper T, Dvorak CC, Chan R, Xicoy B, Germing U, Kojima S, Manabe A, Dworzak M, De Moerloose B, Starý J, Smith OP, Masetti R, Catala A, Bergstraesser E, Ussowicz M, Fabri O, Baruchel A, Cavé H, Zwaan M, Locatelli F, Hasle H, van den Heuvel-Eibrink MM, Flotho C, Yoshimi A
      Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.
      25552679 Haematologica, 2015 Jan. : 100(1)17-22 PMCID:PMC4281308
    • Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI
      AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
      24771494 Cancer, 2014 Aug. 15 : 120(16)2482-9 PMCID:PMC4126862
    • Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI
      AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
      24771494 Cancer, 2014 Aug. 15 : 120(16)2482-9 PMCID:PMC4126862
    • Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI
      AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
      24771494 Cancer, 2014 Aug. 15 : 120(16)2482-9 PMCID:PMC4126862
    • Faulk K, Gore L, Cooper T
      Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.
      24639021 Paediatric drugs, 2014 June : 16(3)213-27
    • Faulk K, Gore L, Cooper T
      Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.
      24639021 Paediatric drugs, 2014 June : 16(3)213-27
    • Faulk K, Gore L, Cooper T
      Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.
      24639021 Paediatric drugs, 2014 June : 16(3)213-27
    • Nickel RS, Keller F, Bergsagel J, Cooper T, Daves M, Sabnis H, Lew G
      Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
      24357218 Pediatric blood & cancer, 2014 May : 61(5)810-4 PMCID:PMC4317248
    • Nickel RS, Keller F, Bergsagel J, Cooper T, Daves M, Sabnis H, Lew G
      Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
      24357218 Pediatric blood & cancer, 2014 May : 61(5)810-4 PMCID:PMC4317248
    • Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML
      Mutations in GATA2 are rare in juvenile myelomonocytic leukemia.
      24578498 Blood, 2014 Feb. 27 : 123(9)1426-7 PMCID:PMC3938154
    • Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML
      Mutations in GATA2 are rare in juvenile myelomonocytic leukemia.
      24578498 Blood, 2014 Feb. 27 : 123(9)1426-7 PMCID:PMC3938154
    • Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML
      Mutations in GATA2 are rare in juvenile myelomonocytic leukemia.
      24578498 Blood, 2014 Feb. 27 : 123(9)1426-7 PMCID:PMC3938154
    • Summers RJ, Abramowsky CR, Cooper TM
      Correlating pathology with the clinical symptoms of methotrexate-induced leukoencephalopathy in a child with relapsed T-cell acute lymphoblastic leukemia.
      23274378 Journal of pediatric hematology/oncology, 2014 Jan. : 36(1)e19-22
    • Summers RJ, Abramowsky CR, Cooper TM
      Correlating pathology with the clinical symptoms of methotrexate-induced leukoencephalopathy in a child with relapsed T-cell acute lymphoblastic leukemia.
      23274378 Journal of pediatric hematology/oncology, 2014 Jan. : 36(1)e19-22
    • Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, Narendran A
      Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
      23176524 Leukemia & lymphoma, 2013 July : 54(7)1505-16
    • Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis J, Whitlock JA
      Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
      23335239 Pediatric blood & cancer, 2013 July : 60(7)1141-7 PMCID:PMC4605828
    • Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, Narendran A
      Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
      23176524 Leukemia & lymphoma, 2013 July : 54(7)1505-16
    • Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis J, Whitlock JA
      Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
      23335239 Pediatric blood & cancer, 2013 July : 60(7)1141-7
    • Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis J, Whitlock JA
      Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
      23335239 Pediatric blood & cancer, 2013 July : 60(7)1141-7 PMCID:PMC4605828
    • Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, Narendran A
      Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
      23176524 Leukemia & lymphoma, 2013 July : 54(7)1505-16
    • McElroy AK, Hilinski JA, Abramowsky CR, Jaffe R, Park SI, Shehata BM, Cooper TM
      Bacillary Angiomatosis in Patients With Cancer: A Pediatric Case Report and a Review of the Literature.
      26619465 Journal of the Pediatric Infectious Diseases Society, 2013 June : 2(2)175-8
    • McElroy AK, Hilinski JA, Abramowsky CR, Jaffe R, Park SI, Shehata BM, Cooper TM
      Bacillary Angiomatosis in Patients With Cancer: A Pediatric Case Report and a Review of the Literature.
      26619465 Journal of the Pediatric Infectious Diseases Society, 2013 June : 2(2)175-8
    • Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ
      Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
      22887831 Pediatric blood & cancer, 2012 Dec. 15 : 59(7)1252-8
    • Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ
      Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
      22887831 Pediatric blood & cancer, 2012 Dec. 15 : 59(7)1252-8
    • Watt TC, Cooper T
      Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
      22052552 Pediatric blood & cancer, 2012 Oct. : 59(4)756-7
    • Watt TC, Cooper T
      Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
      22052552 Pediatric blood & cancer, 2012 Oct. : 59(4)756-7
    • Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A
      AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
      21766293 Cancer, 2012 Feb. 1 : 118(3)761-9
    • Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A
      AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
      21766293 Cancer, 2012 Feb. 1 : 118(3)761-9
    • Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, Kadota R, Cooper T, Shen V, Dahl G, Thottassery JV, Jeha S, Maloney K, Paul JA, Barry E, Carroll WL, Gaynon PS
      Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
      21967976 Blood, 2011 Dec. 1 : 118(23)6043-9 PMCID:PMC3731655
    • Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, Kadota R, Cooper T, Shen V, Dahl G, Thottassery JV, Jeha S, Maloney K, Paul JA, Barry E, Carroll WL, Gaynon PS
      Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
      21967976 Blood, 2011 Dec. 1 : 118(23)6043-9 PMCID:PMC3731655
    • Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, Kadota R, Cooper T, Shen V, Dahl G, Thottassery JV, Jeha S, Maloney K, Paul JA, Barry E, Carroll WL, Gaynon PS
      Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
      21967976 Blood, 2011 Dec. 1 : 118(23)6043-9 PMCID:PMC3731655
    • Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A
      Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.
      21949608 OncoTargets and therapy, 2011 : 4149-68 PMCID:PMC3176174
    • Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A
      Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.
      21949608 OncoTargets and therapy, 2011 : 4149-68 PMCID:PMC3176174
    • Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML
      Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
      18954903 Leukemia research, 2009 March : 33(3)355-62 PMCID:PMC2692866
    • Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML
      Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
      18954903 Leukemia research, 2009 March : 33(3)355-62 PMCID:PMC2692866
    • Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML
      Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
      18954903 Leukemia research, 2009 March : 33(3)355-62 PMCID:PMC2692866
    • Cooper TM
      Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
      18516261 Therapeutics and clinical risk management, 2007 Dec. : 3(6)1135-41 PMCID:PMC2387290
    • Cooper TM
      Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
      18516261 Therapeutics and clinical risk management, 2007 Dec. : 3(6)1135-41 PMCID:PMC2387290
    • Cooper T, Ayres M, Nowak B, Gandhi V
      Biochemical modulation of cytarabine triphosphate by clofarabine.
      15723262 Cancer chemotherapy and pharmacology, 2005 April : 55(4)361-8
    • Cooper T, Ayres M, Nowak B, Gandhi V
      Biochemical modulation of cytarabine triphosphate by clofarabine.
      15723262 Cancer chemotherapy and pharmacology, 2005 April : 55(4)361-368
    • Cooper T, Ayres M, Nowak B, Gandhi V
      Biochemical modulation of cytarabine triphosphate by clofarabine.
      15723262 Cancer chemotherapy and pharmacology, 2005 April : 55(4)361-368
    • Cooper T, Kantarjian H, Plunkett W, Gandhi V
      Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
      15571270 Nucleosides, nucleotides & nucleic acids, 2004 Oct. : 23(8-9)1417-23
    • Cooper T, Kantarjian H, Plunkett W, Gandhi V
      Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
      15571270 Nucleosides, nucleotides & nucleic acids, 2004 Oct. : 23(8-9)1417-23

Overview

Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

Nova Southeastern University Osteopathic Medicine, Fort Lauderdale

Residency

Pediatrics, University of South Alabama, Mobile

Fellowship

Pediatric Hematology Oncology, UT MD Anderson Cancer Center, Houston

Research Focus Area

Cancer biology